The upregulation of serine palmitoyltransferase Sptlc2 and ceramide synthases CerS4-6, as well as the enrichment in dihydroceramides suggests an increase in de novo SL synthesis in both NASH models. The gene discussed is TLCD3B; the disease is metabolic dysfunction-associated steatohepatitis.